Amylyx Launches $350M Public Offering to Fund Avexitide Launch
AMLX has more than doubled off its 52-week low of $7.63 on elevated volume (12× avg).
Summary
Amylyx is raising $350 million in a public offering to fund the commercial launch of avexitide after positive Phase 3 results. The offering is priced near the stock's 52-week high, reflecting strong demand but diluting existing shareholders.
Key Events · Financing and Capital Events · AMLX
-
$350M Public Offering
Amylyx is offering $350 million of common stock, with underwriters holding a 30-day option for an additional $52.5 million. The offering is being conducted under the company's existing shelf registration statement.
-
Use of Proceeds
Net proceeds will fund the potential commercial launch of avexitide in the U.S., including securing additional manufacturing capacity, and for research and development, working capital, and general corporate purposes.
-
Underwriters
Leerink Partners, Morgan Stanley, Guggenheim Securities, and LifeSci Capital are acting as joint bookrunning managers for the offering.
-
Dilution Impact
The offering will dilute existing shareholders. Net tangible book value as of June 30, 2026 was $2.15 per share, so new investors will pay a substantial premium over book value.
Analysis · AMLX · Life Sciences
Amylyx is raising $350 million in a public offering, with underwriters holding a 30-day option for another $52.5 million. The offering comes on the same day the company announced positive Phase 3 LUCIDITY results for avexitide, its lead drug candidate for post-bariatric hypoglycemia. The capital will fund the potential commercial launch of avexitide, including manufacturing capacity, and general corporate purposes. The offering is priced near the stock's 52-week high, reflecting strong investor demand following the clinical success. However, the issuance will dilute existing shareholders, and the company's net tangible book value per share is only $2.15, meaning new investors will pay a substantial premium over book value.
At the time of this filing, AMLX was trading at $35.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.9B. The 52-week trading range was $7.63 to $35.39. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.